Cambridge Healthtech Institute’s 15th Annual

Fragment-Based Drug Discovery

From Hits to Leads and Lessons Learned

April 14-15, 2020



Fragment-based drug discovery (FBDD), a way to find new drug leads based on screening libraries of low molecular weight fragments of drug-like organic compounds, has become a part of most drug discovery teams’ lead generation strategies and is especially well suited for finding hits against newer types of drug targets such as intracellular protein-protein interactions (PPIs). A few small molecule therapeutics on the market can now trace their origin to fragment-based library screens. However the main challenge remains: growing fragment hits into drug leads. A newer complexity is also facing many discovery groups: how to integrate FBDD hits with those from various drug-lead generation campaigns such as traditional high-throughput screening and newer DNA-encoded library applications. Join biophysical and medicinal chemist colleagues to discuss these questions and more at Cambridge Healthtech Institute's Fragment-Based Drug Discovery conference, now in our 15th year, and the oldest FBDD conference in the industry.


Preliminary Agenda

COVALENT FRAGMENTS

How to be Selectively Promiscuous

Jack Taunton, PhD, Professor, Department of Cellular and Molecular Pharmacology, University of California, San Francisco

Covalent Fragments Technology for Drug Lead Generation: Past, Present, and Future

Alexander Statsyuk, PhD, Assistant Professor, Department of Pharmacological and Pharmaceutical Sciences, University of Houston

Electrophile-Fragment Screening for Rapid Covalent Fragment Probe Screening

Nir London, PhD, Senior Scientist, Weizmann Institute of Science

FRAGMENT-BASED LEAD GENERATIONI (AND BEYOND?) STORIES

Fragment Synergies to Deliver Multiple Shots at Moving Targets

ChunWa Chung, PhD, Director, Structural & Biophysical Sciences, GlaxoSmithKline, UK

Some New Experiences in Fragmentology

Rod Hubbard, PhD, Vernalis (R&D) Ltd.

FBDD Approaches for Diverse Series for Novel Cancer Target, Vps34

Jenny Viklund, Director, Protein Science & Drug Design, Sprint Biosciences

Talk Title to be Announced

Valerio Berdini, PhD, Associate Director, Computational Chemistry, Astex

FRAGMENT LIBRARY DESIGN & SCREENING APPROACHES

Delivering and Exploiting Routine Crystal-based XChem Fragment Screening

Frank von Delft, PhD, Principal Beamline Scientist, Diamond Light Source and Structural Genomics Consortium & Professor, Structural Chemical Biology, University of Oxford

Fragment Hits and Leads: More than Meets the Eye

Giordanetto Fabrizio, PhD, Head, Medicinal Chemistry, D.E. Shaw Research

Fragment Screening of GPCRs Using NMR

Isabelle Krimm, PhD, Professor, University of Lyon

* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean


Update History
2019/11/25
Sponsor updated
2019/10/31
Agenda,Sponsor updated